Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RARG | P13631 | 20/20 | 0.89 |
| ▸ | RARB | P10826 | 19/20 | 0.89 |
| ▸ | RARA | P10276 | 18/20 | 0.89 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL382316 | 0.96 | RARG (0.89) | RARGRARBRARA | |
| SCHEMBL381691 | 0.94 | RARG (1.00) | RARGRARBRARA | |
| SCHEMBL381853 | 0.93 | RARG (0.85) | RARGRARBRARA | |
| SCHEMBL382382 | 0.92 | RARG (1.00) | RARGRARBRARA | |
| SCHEMBL381776 | 0.91 | RARG (1.00) | RARGRARBRARA | |
| SCHEMBL381976 | 0.86 | RARG (0.84) | RARGRARBRARA | |
| SCHEMBL382248 | 0.86 | RARG (0.80) | RARGRARBRARA | |
| SCHEMBL382966 | 0.85 | RARG (0.70) | RARGRARBRARA | |
| SCHEMBL382031 | 0.85 | RARG (0.82) | RARGRARBRARA | |
| SCHEMBL381682 | 0.84 | RARG (0.81) | RARGRARBRARA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10980778-B2 | Methods for treating multiple osteochondroma (MO) | Clementia Pharmaceuticals Inc. (CA) | 2021-04-20 | — | — | US | disclosed |
| US-20190275005-A1 | METHODS FOR TREATING MULTIPLE OSTEOCHONDROMA (MO) | Clementia Pharmaceuticals Inc. (CA) | 2019-09-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10980778-B2 | Methods for treating multiple osteochondroma (MO) | UTRN, VHL, SOST | RARG 1720/4885RARB 1620/4885RARA 1990/4885 |
| US-20190275005-A1 | METHODS FOR TREATING MULTIPLE OSTEOCHONDROMA (MO) | UTRN, VHL, SOST | RARG 1720/4885RARB 1620/4885RARA 1990/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.